Abstract
AbstractAcute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a common cause for emergency department (ED) visits. Still, large scale studies that assess the management of AECOPD in the ED are limited. Our aim was to evaluate treatment characteristics of AE-COPD in the ED on a national scale. A prospective study as part of the COPD Israeli survey, conducted between 2017 and 2019, in 13 medical centers. Patients hospitalized with AECOPD were included and interviewed. Clinical data related to their ED and hospital stay were collected. 344 patients were included, 38% females, mean age of 70 ± 11 years. Median (IQR) time to first ED treatment was 59 (23–125) minutes and to admission 293 (173–490) minutes. Delayed ED treatment (> 1 h) was associated with older age (p = 0.01) and lack of a coded diagnosis of COPD in hospital records (p = 0.01). Long ED length-of-stay (> 5 h) was linked with longer hospitalizations (p = 0.01). Routine ED care included inhalations of short-acting bronchodilators (246 patients, 72%) and systemic steroids (188 patients, 55%). Receiving routine ED care was associated with its continuation during hospitalization (p < 0.001). In multivariate analysis, predictors for patients not receiving routine care were obesity (adjusted odds ratio 0.5, 95% CI 0.3–0.8, p = 0.01) and fever (AOR 0.3, 95% CI 0.1–0.6, p < 0.01), while oxygen saturation < 91% was an independent predictor for ED routine treatment (AOR 3.6, 95% CI 2.1–6.3, p < 0.01). Our findings highlight gaps in the treatment of AECOPD in the ED on a national scale, with specific predictors for their occurrence.
Funder
The Israeli Ministry of Health
GlaxoSmithKline
Boehringer Ingelheim
AstraZeneca
Novartis
Kamada
Pfizer
Tel Aviv University
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. 2023 GOLD Report. Global Initiative for Chronic Obstructive Lung Disease-GOLD. https://goldcopd.org/2023-gold-report-2/. Accessed 15–10–2023
2. Safiri S, Carson-Chahhoud K, Noori M, Nejadghaderi SA, Sullman MJM, Heris JA, Ansarin K, Mansournia MA, Collins GS, Kolahi A-A, Kaufman JS (2022) Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990–2019: results from the global burden of disease study 2019. BMJ 378:e069679. https://doi.org/10.1136/bmj-2021-069679
3. Wedzicha JA, Miravitlles M, Hurst JR, Calverley PMA, Albert RK, Anzueto A, Criner GJ, Papi A, Rabe KF, Rigau D, Sliwinski P, Tonia T, Vestbo J, Wilson KC, Krishnan JA (2017) Management of COPD Exacerbations: a European respiratory society/American thoracic society guideline. Eur Respir J. https://doi.org/10.1183/13993003.00791-2016
4. National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management; NICE, 2019. https://www.nice.org.uk/guidance/NG115. Accessed 01–11–2023
5. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157(5):1418–1422. https://doi.org/10.1164/ajrccm.157.5.9709032
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献